Related references
Note: Only part of the references are listed.Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay
Nina Svensen et al.
PLOS NEGLECTED TROPICAL DISEASES (2021)
DNA Topoisomerase 3α Is Involved in Homologous Recombination Repair and Replication Stress Response in Trypanosoma cruzi
Hellida Marina Costa-Silva et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
In Vivo Analysis of Trypanosoma cruzi Persistence Foci a Single-Cell Resolution
Alexander Ward et al.
MBIO (2020)
Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model
Yannick Parmentier et al.
XENOBIOTICA (2019)
Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
James Nyagwange et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2019)
Screening the Medicines for Malaria Venture Pathogen Box against piroplasm parasites
Arifin Budiman Nugraha et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2019)
Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery
Martina Maccesi et al.
PARASITES & VECTORS (2019)
Screening the Pathogen Box for Identification of New Chemical Agents with Anti-Fasciola hepatica Activity
Claudia Machicado et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole
James A. Watson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Unpacking the Pathogen Box-An Open Source Tool for Fighting Neglected Tropical Disease
Clinton G. L. Veale
CHEMMEDCHEM (2019)
3-pyridyl inhibitors with novel activity against Trypanosoma cruzi reveal in vitro profiles can aid prediction of putative cytochrome P450 inhibition
Melissa L. Sykes et al.
SCIENTIFIC REPORTS (2018)
A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients
Maan Zrein et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery
Lorna M. MacLean et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure
Fernando J. Sanchez-Valdez et al.
ELIFE (2018)
Clinical and veterinary trypanocidal benzoxaboroles target CPSF3
Richard J. Wall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery
Clinton G. L. Veale et al.
MEDCHEMCOMM (2018)
Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors
Taissa Vila et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles
Alessio Nocentini et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2017)
Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi
Stephen Brand et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers The STOP-CHAGAS Trial
Carlos A. Morillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Experimental and Clinical Treatment of Chagas Disease: A Review
Policarpo Ademar Sales Junior et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2017)
Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery
Sandra Duffy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions
Christopher A. Lipinski
ADVANCED DRUG DELIVERY REVIEWS (2016)
Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides
Stephanie Russell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
Shilpi Khare et al.
NATURE (2016)
Molecular Diagnosis of Chagas Disease in Colombia: Parasitic Loads and Discrete Typing Units in Patients from Acute and Chronic Phases
Carolina Hernandez et al.
PLOS NEGLECTED TROPICAL DISEASES (2016)
Assessing anti-T. cruzi candidates in vitro for sterile cidality
Monica Cal et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2016)
SQ109, a New Drug Lead for Chagas Disease
Phercyles Veiga-Santos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The use of posaconazole against Chagas disease
Israel Molina et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2015)
Translational challenges of animal models in Chagas disease drug development: a review
Eric Chatelain et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease
Jennifer Riley et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes
Melissa L. Sykes et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2015)
Oxa, Thia, Heterocycle, and Carborane Analogues of SQ109: Bacterial and Protozoal Cell Growth Inhibitors
Kai Li et al.
ACS INFECTIOUS DISEASES (2015)
Chagas Disease Drug Discovery: Toward a New Era
Eric Chatelain
JOURNAL OF BIOMOLECULAR SCREENING (2015)
Tropical diseases and the poor Neglected tropical diseases are a public health problem for developing and developed countries alike
Philip Hunter
EMBO REPORTS (2014)
New, Combined, and Reduced Dosing Treatment Protocols Cure Trypanosoma cruzi Infection in Mice
Juan M. Bustamante et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease
Israel Molina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development
Carolina B. Moraes et al.
SCIENTIFIC REPORTS (2014)
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: A Suitable Scaffold for the Development of Noncamptothecin Topoisomerase I (Top1) Inhibitors
Sabrina Taliani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A divalent protecting group for benzoxaboroles
Brett VanVeller et al.
RSC ADVANCES (2013)
Identification of Compounds with Anti-Proliferative Activity against Trypanosoma brucei brucei Strain 427 by a Whole Cell Viability Based HTS Campaign
Melissa L. Sykes et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Antitrypanosomal Activity of Fexinidazole, a New Oral Nitroimidazole Drug Candidate for Treatment of Sleeping Sickness
Marcel Kaiser et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
TRIAL WATCH Phase III and submission failures: 2007-2010
John Arrowsmith
NATURE REVIEWS DRUG DISCOVERY (2011)
SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis
Robert T. Jacobs et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
Discovery of Novel Orally Bioavailable Oxaborole 6-Carboxamides That Demonstrate Cure in a Murine Model of Late-Stage Central Nervous System African Trypanosomiasis
Bakela Nare et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Overview of DNA Repair in Trypanosoma cruzi, Trypanosoma brucei and Leishmania major
Danielle Gomes Passos-Silva et al.
JOURNAL OF NUCLEIC ACIDS (2010)
In Vitro Solubility Assays in Drug Discovery
Edward H. Kerns et al.
CURRENT DRUG METABOLISM (2008)
Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis)
Jose A. Castro et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2006)
Studies on repository compound stability in DMSO under various conditions
XH Cheng et al.
JOURNAL OF BIOMOLECULAR SCREENING (2003)
Share Paper
